Roadsaver颈动脉支架十年欧洲经验:系统综述与探索性荟萃分析
BACKGROUND: Dual-layer micromesh (DLMM) carotid stents were developed to enhance plaque scaffolding and reduce peri-procedural embolization during carotid artery stenting (CAS).…
要点
- Roadsaver双层微网支架欧洲实践中30天卒中率1.6%、死亡率0.5%。
- 荟萃分析未发现Roadsaver与第一代支架或C-Guard在临床结局上有显著差异。
- 支架内再狭窄分析受定义、影像方法和随访时间异质性限制。
核心结论
- Roadsaver双层微网支架在欧洲实践中与较低的30天卒中和死亡发生率相关。
- 探索性合并分析未发现Roadsaver与第一代支架或不同双层微网装置间存在显著差异。
- 对比研究数量少、支架内再狭窄评估异质性和以观察性证据为主限制了结论确定性。
研究设计与样本
- 系统检索PubMed、Embase和Medline,纳入2014年1月1日至2024年12月31日发表的欧洲研究。
- 纳入报告经股动脉颈动脉支架术使用Roadsaver的成年颅外新发颈动脉狭窄患者,症状性或无症状性。
- 比较分析限于报告Roadsaver与第一代支架或C-Guard配对结局的研究。
- 合并效应用Peto比值比和随机效应DerSimonian-Laird模型计算。
主要发现
- 全部研究中30天卒中发生率为1.6%,30天死亡发生率为0.5%。
- 荟萃分析显示Roadsaver与第一代支架在30天卒中或死亡上无统计学显著差异,异质性低。
- 支架内再狭窄比较显示Roadsaver与第一代支架或Roadsaver与C-Guard间均无显著差异。
- 支架内再狭窄分析受定义、影像模态和随访时间明显异质性限制。
关键数值与推荐
- 主要终点为30天卒中和死亡;次要终点为约12个月时≥50%支架内再狭窄,按各研究定义。
临床怎么用
- Roadsaver的安全性与增强斑块支撑和栓塞保护的机制数据支持其用于常规颈动脉支架术,包括复杂解剖。
- 研究结果强化双层微网技术作为当代标准选择而非实验性替代。
- 需标准化支架内再狭窄评估和足够把握度的随机试验来指导颈动脉血运重建的器械选择。
局限性
- 对比研究数量少。
- 支架内再狭窄评估存在异质性。
- 证据基础以观察性研究为主,显著限制发现确定性。
- 需要更大规模、严格设计的比较研究和随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual-layer micromesh (DLMM) carotid stents were developed to enhance plaque scaffolding and reduce peri-procedural embolization during carotid artery stenting (CAS). Although Roadsaver is widely used in contemporary European practice, comparative evidence against first-generation stents (FGSs) and other DLMM devices remains limited. This study systematically reviews the European experience with Roadsaver and performs an exploratory meta-analysis of 30-day clinical outcomes and in-stent restenosis (ISR). METHODS: A systematic search of PubMed, Embase, and Medline identified European studies published between January 1, 2014 and December 31, 2024 reporting transfemoral CAS using the Roadsaver stent. Adult patients with extracranial, de novo carotid stenosis-symptomatic or asymptomatic-were included. Comparative analyses were limited to studies reporting paired outcomes for Roadsaver versus FGSs or C-Guard. Primary endpoints were 30-day stroke and death; the secondary endpoint was ≥50% ISR at approximately 12 months, as defined by each study. Pooled effects were calculated using Peto odds ratios with random-effects DerSimonian-Laird models. RESULTS: Twenty-two studies comprising 3539 Roadsaver procedures were included in the qualitative review; 5 studies met criteria for quantitative pooling. Across all studies, 30-day stroke and death occurred in 1.6% and 0.5% of patients, respectively. Meta-analysis showed no statistically significant differences in 30-day stroke or death between Roadsaver and FGSs, with low heterogeneity. In-stent restenosis comparisons similarly demonstrated no significant differences between Roadsaver and FGSs or between Roadsaver and C-Guard; however, ISR analyses were limited by marked heterogeneity in definitions, imaging modalities, and follow-up timing. CONCLUSIONS: Roadsaver DLMM stenting in European practice is associated with low 30-day stroke and death rates. Exploratory pooled analyses did not identify significant differences between Roadsaver and FGSs or between DLMM devices; however, the small number of comparative studies, variability in ISR assessment, and predominantly observational evidence base substantially limit the certainty of these findings. Larger, rigorously designed comparative studies, and randomized trials are needed to determine whether clinically meaningful differences exist between carotid stent platforms.Clinical impactIn this paper, transfemoral CAS with the Roadsaver dual-layer micromesh stent was associated with low 30-day stroke and death rates in European practice. Comparative analyses did not demonstrate significant differences versus first-generation stents or between DLMM devices; however, the observed safety profile, combined with mechanistic data on enhanced plaque scaffolding and embolic protection, supports the use of Roadsaver in routine CAS, including complex anatomies. These findings reinforce DLMM technology as a contemporary standard option rather than an experimental alternative, while underscoring the need for standardized ISR assessment and adequately powered randomized trials to guide device selection in carotid revascularization.
引用
- Mastrangelo G, Di Martino G, Marzullo A, et al. Ten Years of European Experience With Roadsaver Carotid Stent: A Systematic Review of Literature and Exploratory Meta-Analysis. J Endovasc Ther. 2026. PMID: 42464753. doi:10.1177/15266028261453269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。